Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

ClinicalTrials.gov ID: NCT00090987

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00090987. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial Of Imatinib Mesylate (Gleevec) In Patients With HIV Related Kaposi's Sarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with HIV-related Kaposi's sarcoma.

Study identification

NCT ID: NCT00090987
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AIDS Malignancy Consortium; Network
Enrollment: 30 participants

Conditions and interventions

Conditions

Sarcoma

Interventions

imatinib mesylate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 120 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2005 (Type not available)
Primary completion: Dec 2009 (Actual)
Completion: Dec 2009 (Actual)
Last update posted: Jun 6, 2018

2005 – 2009

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 14

Facility	City	State	ZIP	Site status
Moores UCSD Cancer Center	La Jolla	California	92093-0658	—
USC/Norris Comprehensive Cancer Center and Hospital	Los Angeles	California	90089-9181	—
Jonsson Comprehensive Cancer Center at UCLA	Los Angeles	California	90095-1781	—
Desert Regional Medical Center Comprehensive Cancer Center	Palm Springs	California	92262	—
UCSF Comprehensive Cancer Center	San Francisco	California	94115	—
University of Miami Sylvester Comprehensive Cancer Center - Miami	Miami	Florida	33136	—
Robert H. Lurie Comprehensive Cancer Center at Northwestern University	Chicago	Illinois	60611-3013	—
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Baltimore	Maryland	21231-2410	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Siteman Cancer Center at Barnes-Jewish Hospital	St Louis	Missouri	63110	—
Memorial Sloan - Kettering Cancer Center	New York	New York	10021	—
Albert Einstein Cancer Center at Albert Einstein College of Medicine	The Bronx	New York	10461	—
Case Comprehensive Cancer Center	Cleveland	Ohio	44106-5065	—
Joan Karnell Cancer Center at Pennsylvania Hospital	Philadelphia	Pennsylvania	19106	—
Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center	Seattle	Washington	98101	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00090987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 6, 2018 · Synced Nov 13, 2026